PRODUCT OVERVIEW

Innovation Pharma is developing Brilacidin—a first-in-class immunomodulatory drug candidate with anti-inflammatory and antimicrobial therapeutic applications.

Brilacidin has completed multiple clinical trials, comprising over 500 patients treated to date, and has received special FDA designations, including Fast Track. Brilacidin has the potential to address areas of unmet need and capture sizable commercial opportunities.

Click here (pdf) for a Corporate Overview of Innovation Pharma.